Leishmanicidal Activity of Films Containing Paromomycin and Gentamicin Sulfate both In Vitro and In Vivo
Abstract
Background: Based on the efficacy of paromomycin ointment and recent ongoing clinical trials of combination of paromomycin and gentamicin, a new physical form of films of the paromomycin and gentamicin was prepared and anti-Leishmania activities of the prepared films were assessed in vitro and in vivo.
Methods: Paromomycin 15% and gentamicin 0.5% was incorporated in a film using ethyl cellulose and HPMC (Hydroxyl Propyl Methyl Cellulose). In order to assess the drug release and anti-Leishmania activities of the preparation, a clone L. major parasite was established using a set of modified NNN medium without overlay liquid layer. Therapeutic effects of the films were evaluated using Balb/c mice model. The mice were inoculated with 2×106 L. major promastigotes (MRHO/IR/75/ER) and then when the lesions developed the mice were randomly divided in 3 groups, 10 mice per group, and treated with either perpetrated films or placebo for 28 days or left untreated.
Results: Growth inhibition of cloned promastigotes showed that the films have enough releasing capacity and in vivo system, the films containing paromomycin and gentamicin was able to reduce the lesion size and induced complete cure in 80% of the mice but relapse was seen in 60% of the cured mice and overall 50% cure rate was seen during 20 weeks period of the study.
Conclusion: It seems that the prepared films might be further used in human clinical trials.
Desjeux P. Human leishmaniasis: epidemiology and public health aspects. World Health Stat Q. 1992;45(2-3):267-75.
Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, Hooshmand B, Gorouhi F, Rashighi-Firoozabadi M, Dowlati Y. Imiquimod in combination,with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol. 2006 Dec; 142 (12): 1575-9.
Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M.Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistantm Leishmania tropica parasites. PLoS Med. 2006;3(5):e162. Epub 2006 Apr18.
Croft SL, Coombs GH. Leishmaniasis-- current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003; 19(11):502-8.
Asilian A, Jalayer T, Nilforooshzadeh M, GhassemiRL, Peto R,Wayling S, et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the IslamicRepublic of Iran.Bull World Health Organ. 2003; 81(5):353-9.
Jaafari MR, Bavarsad N, Bazzaz BS, Samiei A, Soroush D, Ghorbani S, et al. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob Agents Chemother. 2009; 53(6): 2259-65.
Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res. 2006;123(3):399-410.
Armijos RX, Weigel MM, Calvopiña M, ManchenoM, Rodriguez R (2004). Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop. 91(2): 153-160.
Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zâatour A, Ben Alaya N, Haj Hamida NB, El Ahmadi Z, Downs MT, Smith PL, Dellagi K, Grögl M. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Neg Trop Dis. 2009;3(5):e432. Epub 2009May 5.
Khamesipour A, Rafati S, Davoudi N, Mahboudi F and Modabber F. Leishmaniasis vaccine candidates for development: Global Overview, Indian J Med Res 123, March 2006, pp 423-438.
Noazin S, Modabber F, Khamesipour A, Smith PG,Moulton LH, Nasseri K, Sharifi I, Khalil EA, Bernal ID, Antunes CM, Kieny MP, Tanner M. First generation leishmaniasis vaccines: a review of field efficacy trials. vaccine.2008 9;26(52):6759-67. Epub 2008 Oct 23.
Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol. 1996; 14(5):417-23.Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, Modabber F, Sharifi I, Khalil EA, Bernal ID, Antunes CM, Smith PG. Efficacy of killed wholeparasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine. 2009 30; 27(35):4747-53. Epub 2009 Jun 18.
Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled, trials. J Am Acad Dermatol. 2007;57(2):335.e1-29. Epub 2007 Mar 6.
Modabber F, Buffet PA, Torreele E, Milon G, Croft SL. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol Dis. 2007 Apr 24;6:3.
Buffet P, Caumes E, Gentilini M. [Treatment of localized cutaneous leishmaniasis]. Ann Dermatol Venereol. 1994; 121(6-7): 503-11.
Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliaro P. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg. 1995;53(6):648-51.
Shazad B, Abbaszadeh B, Khamesipour A. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol. 2005;15(2):85-7.
Grogl M, Schuster BG, Ellis WY, Berman JD. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J Parasitol. 1999; 85(2):354-9.
Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, Berman JD, English CK, Grogl M. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J TropMed Hyg. 2002;66(2):147-51.
| Files | ||
| Issue | Vol 6 No 3 (2011) | |
| Section | Articles | |
| Keywords | ||
| Cutaneous leishmaniasis Paromomycin Gentamicin Drug Film | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
